These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 10022026

  • 1. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
    Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M.
    Methods Find Exp Clin Pharmacol; 1998 Nov; 20(9):739-42. PubMed ID: 10022026
    [Abstract] [Full Text] [Related]

  • 2. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 3. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 01; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 4. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 01; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 5. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

  • 6. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
    El Hilali N, Rubio N, Blanco J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1253-8. PubMed ID: 15709196
    [Abstract] [Full Text] [Related]

  • 7. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 8. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT, Gan Y, Au JL, Wientjes MG.
    Cancer Res; 1998 Jul 01; 58(13):2777-83. PubMed ID: 9661891
    [Abstract] [Full Text] [Related]

  • 9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 01; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 10. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
    Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI, Dalgleish AG.
    Cancer Res; 2003 Feb 01; 63(3):593-9. PubMed ID: 12566301
    [Abstract] [Full Text] [Related]

  • 11. Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice.
    Zhang ZL, Liu ZS, Sun Q.
    Chin Med J (Engl); 2005 Oct 20; 118(20):1688-94. PubMed ID: 16313753
    [Abstract] [Full Text] [Related]

  • 12. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.
    Clin Cancer Res; 2008 Sep 15; 14(18):5769-77. PubMed ID: 18794086
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
    Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O'Meally R, DeWeese TL, Denmeade SR.
    Prostate; 2004 Feb 15; 58(3):291-8. PubMed ID: 14743469
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 01; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.